Advertisement


Eduardo L. Cazap, MD, PhD, on COVID-19: The View From South America

COVID-19 and Cancer Care

Advertisement

Eduardo L. Cazap, MD, PhD, of the Sociedad Latinoamericana y del Caribe de Oncología Médica, and an international editor on The ASCO Post Editorial Board, talks about the situation in Argentina treating patients with COVID-19, and the 10-country research effort led by the World Health Organization seeking to fast track research on the coronavirus. Filmed April 7, 2020.



Related Videos

COVID-19

Karen E. Knudsen, PhD, MBA, on Delivering Cancer Care During the COVID-19 Pandemic: Report From Philadelphia

Karen E. Knudsen, PhD, MBA, Director of the Sidney Kimmel Cancer Center, talks about what she and her staff have encountered during the COVID-19 crisis and how they and their patients are coping. Filmed March 25, 2020.

Hematologic Malignancies
COVID-19

William A. Wood, MD, MPH, on the New ASH Research Collaborative Data Hub COVID-19 Registry for Hematologic Malignancy

William A. Wood, MD, MPH, of the University of North Carolina at Chapel Hill, and Oversight Group Chair for the new COVID-19 registry, talks about why it was formed, how it can help patients and providers, and how it operates and could evolve in the future. Filmed April 3, 2020.

COVID-19
Global Cancer Care
Skin Cancer

Paolo A. Ascierto, MD, on Cancer Treatment During the COVID-19 Pandemic: The View From Southern Italy

Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori in Naples, Italy, talks about minimizing risks for patients with cancer, prioritizing surgery and other treatments for melanoma, and the state of clinical trials. Filmed April 17, 2020.

Multiple Myeloma
COVID-19

Saad Z. Usmani, MD: In My Experience Question 3

Because of the COVID-19 pandemic, has your management strategy changed for post-transplant consolidation and maintenance therapy in patients with multiple myeloma?

Recorded April 24, 2020.

Leukemia
COVID-19

Laura C. Michaelis, MD: In My Experience Question 1

How has the COVID-19 pandemic changed your approach to the selection of tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia?

Recorded April 24, 2020.

Advertisement

Advertisement




Advertisement